T. Rowe Price Associates
CHTP

T. Rowe Price Associates’s CHELSEA THERAPEUTICS INT'L LTD CHTP Stock Holding History

T. Rowe Price Associates’s Portfolio CHTP Stock Details CHTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-47,300
Closed -$109K – 2498
2013
Q2 		$109K Buy
+47,300
New +$95.6K ﹤0.01% 2328

Other funds holding CHTP

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

T. Rowe Price Associates's CHTP Position: Q3 2013 in Review

T. Rowe Price Associates sold out of CHELSEA THERAPEUTICS INT'L LTD (CHTP) in Q3 2013, closing a stake of 47,300 shares — an estimated $109K sold.

T. Rowe Price Associates first reported a position in CHTP in Q2 2013 and held it in 1 quarter. The position peaked at $109K in Q2 2013. 69 funds tracked by Wall St. Rank hold CHTP as of Q3 2013.

  • T. Rowe Price Associates reported no remaining CHELSEA THERAPEUTICS INT'L LTD position as of Q3 2013 after selling out during the quarter.
  • T. Rowe Price Associates sold 47,300 CHELSEA THERAPEUTICS INT'L LTD shares in Q3 2013, an estimated $109K.
  • T. Rowe Price Associates first reported a position in CHELSEA THERAPEUTICS INT'L LTD in Q2 2013 and held it in 1 quarter.
  • T. Rowe Price Associates's CHELSEA THERAPEUTICS INT'L LTD position peaked at $109K in Q2 2013.
  • 69 funds tracked by Wall St. Rank held CHELSEA THERAPEUTICS INT'L LTD as of Q3 2013.

Based on T. Rowe Price Associates's 13F filing for Q3 2013, filed 14 Nov 2013.